Prostate, Phase II
A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anca Bulgaru, MD
- Andrea Brennan, PA
- Anne Marie Boustani, MD
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS, MD
- Benjamin Newton, MD
- Christina Santore, APRN
- Clarice Grens, APRN
- Curtis Jamison Perry, MD, PhD
- D. Barry Boyd, MD, MS
- Elizabeth Gaa, APRN
- Emily Kopas, APRN, OCN
- Gabriela Spilberg, MD
- Georges El Fakhri, PhD, DABR
- Harold Tara Jr, MD
- Jadwiga Kretowicz, APRN
- Jason Haldas, MD
- Johanna LaSala, MD
- Joseph Kim, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Katherine Harvey, MD, MPH
- Kert Sabbath, MD, FACP
- Kira Grogg, PhD
- Larisa Fleysher, APRN
- Lawrence Saperstein, MD
- Lynn Mastrianni, APRN
- Matthew Austin, MD
- Michael Grant, MD
- Michael Hurwitz, MD, PhD
- Ming-Kai Chen, MD, PhD
- Moses Quinn Wilks, PhD
- Neal Fischbach, MD
- Robert Legare, MD
- Robert Matera, MD
- Sara Anastasio, APRN, RN
- Sarah Carlson, PA
- Sarah Thomen, APRN
- Sharynn Hall, MD, PhD
- Stacey LaRosa, APRN
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Virginia Syombathy, APRN
- Wajih Kidwai, MD, FACP
- William K. Oh, MD
- Yifei Zhang, MD
- Last Updated04/30/2026
- Study IRB#2000041834